The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group

Survival of Patients with Non-small Cell Lung Cancer and Brain Metastases

“…This fact has already been shown by the multiple RTOG dose-finding trials in the 1970s and 1980s [4,5], the Royal College of Radiologists' publication from 1996 [6] and the Cochrane review of 2006 [7]. However, as the Cochrane review points out, there has never been a full randomised controlled trial of supportive care plus or minus WBRT and this information is of utmost importance, particularly in the non-small cell lung cancer group.…”

“…Sir d The GYN GEC-ESTRO Brachytherapy Working Group has recommended contouring guidelines, concepts and terms in three-dimensional magnetic resonance imagebased treatment planning in cervical cancer brachytherapy [1,2], with reports confirming the safety, feasibility, definite advantages, clinical outcome and late toxicities (limited series) [3,4]. We evaluated 24 patients treated with high dose rate brachytherapy who underwent at least one magnetic resonance scan for planning between May 2006 and December 2007 as a part of validation and implementation of the guidelines in a developing country setting.…”

Pro‐gastrin–releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation

“…9 The brain is the initial site of disease recurrence in 5-33% of patients, and is the only site of disease recurrence in Յ 20% of patients. 10,11 Although several randomized trials of prophylactic cranial irradiation (PCI) have attempted to reduce the risk of brain metastasis and to improve survival, to our knowledge its role in the management of patients with SCLC has remained controversial according to the results of each trial. [12][13][14] Recently, the metaanalysis of these trials comparing PCI with no-PCI found that PCI led to a small but significant absolute reduction in mortality (5.4%), and that PCI not only significantly reduced the risk of brain metastasis, but also improved both overall survival (OS) and disease-free survival among patients with SCLC in CR.…”

A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis

“…Treatment response was evaluated through periodic reassessment of PS and neurological function (FN) as described by Borgelt (1980) and the Radiation Therapy Oncology Group (Table 1). Patients were evaluated before treatment-weekly for the first 4 weeks, monthly for 2 or more months and every 3 months thereafter.…”